Login or Register to unlock everything MedSchool has to offer!
Neuro Drugs
 
 
 

Corticosteroids

 
 
  •  
    IV / Oral
    Prednisolone / Prednisone
    Panafcort, Predsone, Sone 
  •  
    IV / IM / Oral
    Methylprednisolone
    Medrol 
  •  
    Oral / IV / Local / Topical
    Betamethasone
    Celestone 
  •  
    IV / Topical
    Hydrocortisone
    Cortef 
  •  
    IV
    Dexamethasone

Overview

    • Mechanism of Action

      Suppress the body's normal inflammatory response through:
    • Reduced monocyte recruitment
    • Suppression of arachidonic acid metabolites - prostaglandin, leukotriene, platelet-activating factor
    • Reduced production of interleukins, TNF-α, GM-CSF
    • Non-Inflammatory Effects of Corticosteroids

    • Increased circulating glucose - ↑gluconeogenesis, ↓glucose usage
    • Redistribution of fats - in face, neck, shoulder
    • ↓ Absorption of Ca²⁺
    • Muscle homeostasis

Clinical Use

    • Indications

    • Acute asthma
    • Exacerbations of COPD
    • Croup
    • Other inflammatory conditions - dermatitides, ulcerative colitis, autoimmune haemolytic anaemia, acute gout, rheumatoid arthritis, seronegative arthritides, systemic lupus erythematosus, polyarteritis nodosa
    • Cerebral oedema
    • Nephrotic syndrome
    • Replacement therapy for adrenocortical insufficiency
    • Immunosuppression post organ transplant
    • Adverse Effects

    • Immunosuppression (risk of infection)
    • Osteoporosis
    • Steroid-induced diabetes mellitus
    • Cushing’s - central obesity, ‘moon’ face, buffalo hump, thin skin, peripheral oedema, striae, bruising
    • CNS - cognitive impairment / emotional instability / fatigue
    • Renal - sodium & water retention / hypertension / oedema
    • GIT - peptic ulceration, nausea / vomiting
    • Muscle wasting
    • Ocular - cataract / glaucoma
    • Signs of Withdrawal

    • Worsening of underlying disease
    • Acute adrenal insufficiency
    • Raised ICP / papilloedema
    • Avoiding Withdrawal

    • Taper the dose by 2.5-5mg prednisone every 3-7 days prior to ceasing.
  • Give in the morning between 6-10am in order to mimic the normal diurnal cycle
Last updated on January 1st, 2017
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Read More...

The information in this section has been adapted in part from the Australian Therapeutic Goods Association website's repository of product information documents, which are available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI.
 Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334:168–175. Calm DB, Reid JL. Antiparkinsonian drugs: pharmacological and therapeutic aspects. Drugs. 1972 Jul 1;4(1-2):49-74. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I, et al. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42 Fenstermacher, N, Levin, M and Ward, T. Pharmacological prevention of migraine. BMJ. 2011; 342: 540-543. Lawrence, ER, Hossain, M and Littlestone, W. Sanomigran for Migraine Prophylaxis; Controlled Multicenter Trial in General Practice. Headache. 1977; 17(3): 109-112.
Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Advances in Neurology. 1986; 44: 713-736.
 Meldrum B, Mechanism of action of valproate. Brain Research Bulletin. 1980; 5(2 Suppl): 579-584. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism. Annals of Neurology. 1985 Nov; 18(5): 537–543. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clinical neuropharmacology. 1998 May 1;21(3):141-51. Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol. 1992 Feb;12(1 Suppl): 23S-35S. Rudick RA, Goelz SE. Beta-Interferon for Multiple Sclerosis. Experimental Cell Research. 2011 May; 317(9): 1301-1311. Saxena, PR and Den Boer, MO. Pharmacology of antimigraine drugs. Journal of Neurology. 1991; 238: S28-S35. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259.
Feedback